Rhythm Pharmaceuticals, Inc.
RYTM
$96.22
-$1.70-1.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.80% | 25.94% | 72.61% | 47.76% | 51.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.80% | 25.94% | 72.61% | 47.76% | 51.28% |
| Cost of Revenue | 88.09% | 29.96% | 17.14% | 58.71% | 31.80% |
| Gross Profit | 64.40% | 25.46% | 81.15% | 46.44% | 53.85% |
| SG&A Expenses | 26.18% | 13.68% | 17.78% | 16.09% | 21.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.85% | 8.51% | 26.85% | 16.07% | 5.67% |
| Operating Income | -11.90% | 1.02% | 0.02% | 0.15% | 13.14% |
| Income Before Tax | -45.66% | 64.97% | -4.69% | -0.43% | 31.95% |
| Income Tax Expenses | -29.65% | -73.33% | -145.92% | -193.48% | -- |
| Earnings from Continuing Operations | -44.55% | 64.99% | -3.98% | 1.18% | 30.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.55% | 64.99% | -3.98% | 1.18% | 30.92% |
| EBIT | -11.90% | 1.02% | 0.02% | 0.15% | 13.14% |
| EBITDA | -12.05% | 0.98% | -0.06% | 0.03% | 13.16% |
| EPS Basic | -36.96% | 65.72% | -3.06% | 3.73% | 33.02% |
| Normalized Basic EPS | -9.02% | 3.16% | -0.64% | 5.05% | 18.82% |
| EPS Diluted | -36.96% | 65.72% | -3.06% | 3.73% | 33.02% |
| Normalized Diluted EPS | -9.02% | 3.16% | -0.64% | 5.05% | 18.82% |
| Average Basic Shares Outstanding | 4.38% | 4.85% | 4.03% | 5.78% | 7.29% |
| Average Diluted Shares Outstanding | 4.38% | 4.85% | 4.03% | 5.78% | 7.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |